Application Nr Approved Date Route Status External Links
ANDA076485 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Severe Recalcitrant Nodular Acne Myorisan Is Indicated For The Treatment Of Severe Recalcitrant Nodular Acne. Nodules Are Inflammatory Lesions With A Diameter Of 5 Mm Or Greater. The Nodules May Become Suppurative Or Hemorrhagic. “severe,” By Definition, 2 Means “many” As Opposed To “few Or Several” Nodules. Because Of Significant Adverse Effects Associated With Its Use, Myorisan Should Be Reserved For Patients With Severe Nodular Acne Who Are Unresponsive To Conventional Therapy, Including Systemic Antibiotics. In Addition, Myorisan Is Indicated Only For Those Patients Who Are Not Pregnant, Because Myorisan Can Cause Severe Birth Defects (See Boxed Contraindications And Warnings ). A Single Course Of Therapy For 15 To 20 Weeks Has Been Shown To Result In Complete And Prolonged Remission Of Disease In Many Patients. 1,3,4 If A Second Course Of Therapy Is Needed, It Should Not Be Initiated Until At Least 8 Weeks After Completion Of The First Course, Because Experience Has Shown That Patients May Continue To Improve While Off Myorisan. The Optimal Interval Before Retreatment Has Not Been Defined For Patients Who Have Not Completed Skeletal Growth (See Warnings: Skeletal: Bone Mineral Density , Hyperostosis , Premature Epiphyseal Closure ).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Isotretinoin ISOTRETINOIN ZINC3792789

Comments